陕西康惠制药股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 被担保人名称：陕西方元医药生物有限公司（以下简称"方元医药"） 本次担保金额：400 万元人民币；实际为其提供的担保余额（含本次担 保）：1,500 万元 证券代码：603139 证券简称：康惠制药 公告编号：2023-045 一、担保情况概述 陕西康惠制药股份有限公司（以下简称"公司"）于 2023 年 4 月 28 日及 2023 年 5 月 30 日，召开第五届董事会第五次会议、第五届监事会第五次会议及 2022 年年度股东大会，审议通过《关于 2023 年度预计为控股子公司提供担保的议案》， 同意公司为控股子公司在金融机构申请的综合授信额度提供不超过 20,800 万元 的连带责任保证，其中，同意为方元医药在金融机构申请的授信，提供不超过 2,000 万元的连带责任保证（具体内容详见公司于 2023 年 4 月 29 日、5 月 31 日在上海证券交易所网站披露的 2023-013、2023-0 ...

证券代码：603139 证券简称：康惠制药 公告编号：2023-044 一、投资合伙企业概述 陕西康惠制药股份有限公司（以下简称"公司"），于 2018 年 9 月 18 日经 公司总经理办公会审议通过关于投资参股西安润沣医药投资合伙企业（有限合 伙）（以下简称"润沣合伙"）的事项，并于当日签署了《西安润沣医药投资合 伙企业（有限合伙）合伙协议》（以下简称"《合伙协议》"）。公司作为有限 合伙人出资 1,000 万元投资润沣合伙，出资比例 45.45%【具体内容详见公司于 2018年9月19日、9月20日、10月25日在上海证券交易所网站（www.sse.com.cn） 披露的 2018-039 号、2018-040、2018-048 号公告】。 二、关于延长合伙企业经营期限及基金存续期限的情况 1、延长合伙企业经营期限及基金存续期限情况 润沣合伙原合伙期限于 2023 年 8 月 14 日到期，因投资的项目未能退出，为 保障各方合法权益，保证基金的正常运作和项目的顺利退出，实现最优的基金收 益和合伙人权益，经普通合伙人提议并由全体合伙人一致同意对润沣合伙经营期 限及基金存续期限进行变更。 近期，润沣合伙召开 ...

证券代码：603139 证券简称：康惠制药 公告编号：2023-043 陕西康惠制药股份有限公司 控股股东减持股份时间过半暨减持进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 控股股东持股的基本情况：本次减持计划实施前，陕西康惠控股有限公 司（以下简称"康惠控股"）持有陕西康惠制药股份有限公司（以下简称"公司"） 股份 36,706,237 股，占公司股份总数的 36.75%，控股股东持有的股份来源于公 司首次公开发行前取得的股份，该部分股份已于 2020 年 4 月 21 日解除限售并上 市流通。 减持计划的进展情况：公司于 2023 年 6 月 3 日披露了康惠控股的减持 计划，康惠控股拟通过集中竞价、大宗交易方式合计减持公司股份总数不超过 2,996,400 股，减持比例不超过公司总股本的 3%，具体内容详见公司在上海证券 交易所网站披露的《陕西康惠制药股份有限公司控股股东减持股份计划公告》（公 告编号：2023-027）。截至 2023 年 8 月 11 日，康惠控股本次减持计划实施 ...

证券代码：603139 证券简称：康惠制药 公告编号：2023-023 陕西康惠制药股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间： 2023 年 5 月 18 日（星期四）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 11 日(星期四)至 5 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （irsxkh@163.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 陕西康惠制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司于 202 ...

证券代码：603139 证券简称：康惠制药 公告编号：2023-022 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于参加"2023 年陕西辖区上市公司投资者集体接待日 暨 2022 年度业绩说明会"的公告 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，陕西康惠制药股份有限公 司（以下简称"公司"）将参加由陕西上市公司协会联合深圳市全景网络有限公 司共同举办的"2023 年陕西辖区上市公司投资者集体接待日暨 2022 年度业绩说 明会活动"。 届时，公司董事长及相关高管人员将通过互动平台与投资者进行网络沟通和 交流，欢迎广大投资者踊跃参加！ 二、业绩说明会召开的时间及地点 召开时间：2023 年 5 月 16 日（星期二）15:00-17:00 召开方式：网络在线平台 网络直播地址："全景路演"（http://rs.p5w.net） 重要内容提示： 一、业绩说明会类型 三、参加人员 公司董事长兼总经理、董事会秘书、财务总监及相 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥132,118,911.52, representing a year-on-year increase of 9.25%[4] - The net profit attributable to shareholders decreased by 63.01% to ¥2,339,881.00 for the same period[4] - The basic earnings per share for Q3 2022 was ¥0.02, down 71.43% compared to the previous year[6] - Total operating revenue for the first three quarters of 2022 reached ¥375,140,799.38, an increase of 11.96% compared to ¥335,095,860.67 in the same period of 2021[23] - Net profit for the first three quarters of 2022 was ¥16,131,708.24, a decrease of 19.93% from ¥20,141,367.56 in the same period of 2021[24] - The company reported a total comprehensive income of ¥16,131,708.24 for the period, down from ¥20,141,367.56 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,934,892,041.45, an increase of 4.01% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,934,892,041.45, an increase from RMB 1,860,228,725.79 as of December 31, 2021, reflecting a growth of approximately 3.9%[19] - The company reported a total current liabilities of RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, marking an increase of about 18.9%[19] - The total liabilities of the company amounted to ¥813,525,370.95, an increase from ¥745,202,643.53 in the previous year[21] - The company's total liabilities increased to RMB 378,574,593.81, compared to RMB 318,422,684.80 in the previous year, reflecting an increase of approximately 18.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date increased significantly by 390.29% to ¥46,967,223.22[9] - The net cash flow from operating activities was $46,967,223.22, a significant improvement compared to a net outflow of $16,179,335.15 in the previous period, indicating a positive operational performance[31] - Cash inflow from operating activities totaled ¥437,065,260.94, an increase of 18.93% from ¥367,465,136.03 in the previous year[29] - The cash flow from financing activities generated a net inflow of $68,605,879.86, a decrease from $413,853,902.14 in the previous period, reflecting changes in financing strategies[33] - The cash flow from operating activities showed a positive trend, with cash outflows totaling $390,098,037.72, slightly up from $383,644,471.18, but with improved net cash flow[31] Shareholder Information - The company reported a total of 8,370 common shareholders at the end of the reporting period[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 36.75% of the shares, with 10,000,000 shares pledged[11] - Total equity attributable to shareholders reached ¥1,055,552,796.94, compared to ¥1,046,679,305.61 in the previous year[21] Investments and Subsidiaries - The company established a new subsidiary, Shaanxi Kanghui New Material Technology Co., Ltd., with a registered capital of RMB 3 million, in which it holds a 60% stake[14] - The company's long-term equity investments rose to RMB 141,935,560.11 from RMB 129,401,455.17, showing an increase of approximately 9.5%[17] - The company has made significant investments, with cash paid for fixed assets and other long-term assets amounting to $140,156,681.06, down from $281,219,578.50, reflecting a strategic shift in capital expenditures[31] Expenses - Total operating costs for the first three quarters of 2022 were ¥362,893,894.67, up 14.06% from ¥318,161,562.53 in the previous year[23] - Research and development expenses increased to ¥9,833,820.15, representing a rise of 62.36% compared to ¥6,079,978.65 in the previous year[23]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 243,021,887.86, representing a 13.47% increase compared to CNY 214,168,517.30 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 9.00% to CNY 13,924,730.33 from CNY 15,301,603.92 year-on-year[21]. - The net cash flow from operating activities significantly improved to CNY 49,227,891.40, compared to a negative cash flow of CNY -10,283,812.22 in the previous year, marking a 578.69% increase[21]. - Basic earnings per share decreased by 6.67% to CNY 0.14 from CNY 0.15 in the same period last year[22]. - The weighted average return on net assets decreased by 0.18 percentage points to 1.32% from 1.50% year-on-year[22]. - The total comprehensive income for the first half of 2022 was CNY 13,833,108.26, compared to CNY 16,431,857.19 in the same period of 2021, indicating a decrease[129]. - The company reported a decrease in profit distribution amounting to CNY 7,391,120.00 during the current period[143]. Assets and Liabilities - The total assets of the company increased by 2.23% to CNY 1,901,696,939.18 from CNY 1,860,228,725.79 at the end of the previous year[21]. - The total liabilities increased to CNY 778,940,506.35 from CNY 745,202,643.53, an increase of about 4.5%[113]. - Current liabilities rose to CNY 392,832,813.52, compared to CNY 318,422,684.80, marking an increase of about 23.3%[111]. - Total liabilities decreased to CNY 554,378,937.69 in the latest report from CNY 562,989,407.91 in the previous period[119]. - The total equity increased to CNY 1,047,979,842.71 from CNY 1,041,537,854.45, indicating a growth of 0.6%[119]. Investment and R&D - The company invested 22.07 million yuan in the drug production base and 1.58 million yuan in the drug research center during the reporting period[48]. - Research and development expenses rose by 19.33% to CNY 4,117,696.81, up from CNY 3,450,669.11, reflecting ongoing investment in innovation[52]. - The company is committed to enhancing its R&D capabilities and has implemented effective risk management mechanisms to ensure the successful achievement of product development goals[65]. Market and Industry Context - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,400.78 billion in the first half of 2022, a year-on-year decrease of 0.6%[27]. - The total profit of the pharmaceutical manufacturing sector was CNY 220.91 billion in the same period, reflecting a significant year-on-year decline of 27.6%[27]. - The ongoing COVID-19 pandemic has highlighted the unique value of traditional Chinese medicine, presenting new opportunities for industry growth[30]. Product and Sales Strategy - The company focuses on the research, production, and sales of traditional Chinese medicine, with a strong emphasis on developing chemical drug intermediates[29]. - Key products include compound double flower tablets and Kunfukang capsules, which are included in the national medical insurance directory[33]. - The company operates a dual sales model: professional academic promotion for main products and channel distribution for non-main products[37]. - The company has established a marketing network across 30 provinces in China, enhancing its market presence[38]. Environmental Compliance - The company has established wastewater treatment stations at all three production bases, ensuring compliance with municipal wastewater treatment standards[75]. - The company reported no instances of non-compliance with environmental discharge standards during the reporting period[79]. - The company has committed to maintaining its environmental monitoring through third-party assessments, ensuring that all emissions remain within regulatory limits[79]. Corporate Governance and Shareholder Information - The total number of common shareholders as of the end of the reporting period is 8,747[95]. - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 39.65% of the shares, totaling 39,600,000 shares[97]. - The company has not engaged in any major related party transactions during the reporting period[87]. Financial Instruments and Accounting Policies - The company employs a historical cost method for measuring accounting elements, ensuring reliable measurement of financial data[157]. - Financial assets are classified at initial recognition based on the company's management business model and cash flow characteristics, including those measured at fair value and those at amortized cost[172]. - The company applies expected credit loss model for impairment of financial assets measured at amortized cost and certain debt instruments[176].

Financial Performance - In 2021, the company's operating income reached CNY 442,756,905.81, representing a year-on-year increase of 6.93% compared to CNY 414,071,702.69 in 2020[20]. - The net profit attributable to shareholders of the listed company was CNY 36,481,466.06, up 6.94% from CNY 34,113,730.75 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 42.95% to CNY 15,584,529.04 from CNY 27,317,708.17 in 2020[20]. - The net cash flow from operating activities significantly dropped by 92.08% to CNY 7,418,788.27, compared to CNY 93,722,969.66 in 2020[20]. - Basic earnings per share increased by 8.82% to CNY 0.37 in 2021 from CNY 0.34 in 2020[21]. - The weighted average return on equity rose to 3.57% in 2021, an increase of 0.13 percentage points from 3.44% in 2020[21]. - The net profit attributable to shareholders for Q4 2021 was CNY 14,854,012.34, a significant increase compared to previous quarters[23]. - The company reported a net cash flow from operating activities of CNY 23,598,123.42 in Q4 2021, recovering from negative cash flow in Q1[23]. - The company achieved operating revenue of 442.76 million yuan, an increase of 6.93% year-on-year, and a net profit of 32.997 million yuan, a decrease of 9.49% year-on-year[33]. - The gross profit margin for the pharmaceutical manufacturing segment was 59.09%, a decrease of 1.77 percentage points from the previous year[57]. - Net profit for the period was CNY 32.997 million, a decrease of 9.49% compared to the previous year[54]. - The total number of employees at the parent company and major subsidiaries is 812, with 307 in sales and 217 in production[171]. Assets and Investments - As of the end of 2021, the total assets of the company were CNY 1,860,228,725.79, an increase of 41.87% from CNY 1,311,214,811.94 at the end of 2020[20]. - The net assets attributable to shareholders of the listed company increased by 3.86% to CNY 1,046,679,305.61 from CNY 1,007,732,429.10 in 2020[20]. - The total amount of trading financial assets increased from CNY 55,469,655.31 at the beginning of the year to CNY 119,467,547.42 by year-end, reflecting a change of CNY 63,997,892.11[29]. - The company invested 221.1713 million yuan in the drug production base project and 25.3771 million yuan in the drug research and development center during the reporting period[38]. - The cumulative investment in the drug production base project reached 587.8662 million yuan, while the drug research and development center project reached 42.2002 million yuan by the end of the reporting period[38]. - The company has invested RMB 300 million in Boren Biotechnology, holding an 11.32% stake after the capital increase[106]. - The company’s total assets in its major subsidiaries include RMB 4,775.44 million for Fangyuan Pharmaceutical and RMB 9,467 million for Xinhai Pharmaceutical[112]. Dividends and Shareholder Returns - The company proposed a cash dividend of CNY 0.74 per 10 shares, totaling CNY 7,391,120, which accounts for 20.26% of the net profit attributable to shareholders[6]. - The company has maintained a cash dividend policy, distributing dividends for four consecutive years since its listing, ensuring reasonable returns to shareholders[176]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 196.89 million yuan[144]. Research and Development - Research and development expenses totaled CNY 10.15 million, accounting for 2.29% of total revenue, with no capitalized R&D expenditures[71]. - The number of R&D personnel was 152, making up 18.86% of the total workforce, with a majority aged between 30 and 40 years[72]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing drug efficacy and safety[147]. - The company focuses on R&D in gynecological, orthopedic, and diabetes-related medications, emphasizing market demand and technological innovation[95]. Market Position and Strategy - The company focuses on the pharmaceutical health industry, primarily engaged in the manufacturing of traditional Chinese medicine and chemical drugs, as well as pharmaceutical distribution services[44]. - The company aims to strengthen its market position by focusing on innovative products with high clinical value, which are expected to capture a larger market share[41]. - The company plans to expand its market share in grassroots medical terminals, focusing on products like Zao Ren An Shen Granules and Xiao Yin Granules[88]. - The company is committed to strengthening brand building and improving product market recognition in response to policy changes[88]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for this purpose[198]. Governance and Compliance - The company’s board of directors and management have confirmed the accuracy and completeness of the annual report[5]. - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making processes[134]. - The company has implemented effective information disclosure practices, ensuring all shareholders have equal access to information[136]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[135]. - The company has established a comprehensive internal control management system in accordance with relevant laws and regulations, enhancing governance and protecting investor rights[179]. Industry Trends and Challenges - The pharmaceutical industry in China is experiencing stable growth, with increasing health demands and a shift towards high-quality development amid ongoing policy reforms[41]. - The pharmaceutical industry is facing intensified competition and regulatory changes, necessitating a focus on high-quality development and innovation[83]. - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact its operations if not addressed promptly[126]. - The company faces risks from fluctuations in the prices of traditional Chinese medicine materials, which may adversely affect profitability if not effectively managed[130]. Corporate Social Responsibility - The company donated over 100,000 yuan to charitable causes and provided nearly 80,000 yuan worth of medical supplies to local health centers during the reporting period[188]. - The company has invested in pollution control facilities and monitoring systems to ensure compliance with environmental standards, with no incidents of non-compliance reported[186].

Financial Performance - The company's operating revenue for Q1 2022 was ¥117,729,916.33, representing a year-on-year increase of 21.68%[4] - The net profit attributable to shareholders was ¥8,791,930.72, showing a decrease of 3.44% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥7,837,432.34, which is an increase of 8.51% year-on-year[4] - The net profit for the first quarter of 2022 was CNY 9,153,640.00, an increase of 9.25% compared to CNY 8,376,450.68 in the same period of 2021[25] - The total profit for the first quarter of 2022 was CNY 11,263,451.56, up from CNY 10,452,555.93 in Q1 2021, reflecting a growth of 7.75%[25] - Operating profit for the first quarter of 2022 reached CNY 11,419,086.29, compared to CNY 10,580,400.70 in Q1 2021, indicating an increase of 7.95%[25] - The total comprehensive income for the first quarter of 2022 was CNY 9,153,640.00, compared to CNY 8,376,450.68 in Q1 2021, reflecting an increase of 9.25%[27] Cash Flow - The net cash flow from operating activities reached ¥24,685,902.03, a significant increase of 235.92% compared to the previous year[4] - Cash flow from operating activities generated a net amount of CNY 24,685,902.03, a significant improvement from a net outflow of CNY 18,162,009.79 in the previous year[30] - Cash flow from investing activities resulted in a net outflow of CNY 66,682,283.18, compared to a net outflow of CNY 150,943,959.82 in Q1 2021, showing a reduction in cash outflow[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,838,053,085.62, down 1.19% from the end of the previous year[4] - Total assets as of March 31, 2022, amounted to ¥1,838,053,085.62, slightly down from ¥1,860,228,725.79 at the end of 2021[21] - Total liabilities decreased to ¥713,873,363.36 from ¥745,202,643.53 at the end of 2021, a reduction of 4.2%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,634[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 39.65% of the shares and is subject to a pledge of 900,000 shares[11] Costs and Expenses - Total operating costs for Q1 2022 were ¥106,722,145.56, up from ¥87,868,202.45 in Q1 2021, reflecting a growth of 21.4%[23] - The company's financial expenses surged by 240.70%, primarily due to increased interest expenses on bank loans[7] - Research and development expenses increased to ¥1,445,540.79 in Q1 2022 from ¥1,309,336.56 in Q1 2021, showing a rise of 10.4%[23] Inventory and Receivables - Inventory as of March 31, 2022, was ¥117,081,713.09, a slight decrease from ¥119,892,500.02 at the end of 2021[16] - The company reported a significant increase in accounts receivable, which rose to ¥154,257,777.92 from ¥146,142,009.87, indicating a growth of 5.3%[16] Cash and Equivalents - Cash and cash equivalents as of March 31, 2022, were ¥162,546,662.27, down from ¥203,959,902.14 at the end of 2021, a decrease of 20.3%[16] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 142,546,662.27, down from CNY 437,073,631.33 at the end of Q1 2021[32] Earnings Per Share - Earnings per share remained stable at CNY 0.09 for both basic and diluted earnings per share in Q1 2022[27] Credit Impairment - The company incurred a credit impairment loss of CNY -2,239,461.45 in Q1 2022, compared to CNY -407,830.56 in the same period of 2021, indicating a significant increase in credit losses[25]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 陕西康惠制药股份有限公司 2021 年第三季度报告 证券代码：603139 证券简称：康惠制药 陕西康惠制药股份有限公司 2021 年第三季度报告 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 120,927,343.37 | 4.23 ...